Navigation Links
Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
Date:10/28/2008

Data to be presented at annual ICAAC/IDSA meeting in Washington, D.C.

WASHINGTON, Oct. 28 /PRNewswire/ -- Scientists at NanoBio Corporation have demonstrated for the first time in humans that a novel topical treatment for cold sores (herpes labialis), NB-001, speeds healing of lesions as effectively as the leading oral systemic drugs but without safety or toxicity concerns.

The new data provide the first proof of principle that a topical agent can attain equivalent efficacy rates to oral systemic drugs, according to the NanoBio scientists. Topical treatments are widely considered inferior to oral systemic treatments because they fail to penetrate to the site of infection with adequate drug levels required to subdue infections.

In the study of 482 patients, NB-001 healed lesions 1.3 days faster than placebo as measured by investigators (P=0.006). Results of the randomized, double-blind, placebo-controlled, phase 2b trial are being presented at the 48th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th annual Infectious Diseases Society of America (IDSA) meeting in Washington, D.C.

NB-001 was well tolerated, without safety concerns or adverse events, and was not systemically absorbed. "NB-001 challenges the conventional wisdom that topical therapies are less effective, because NB-001 directly accesses the site of infection in the dermis and epidermis instead of remaining on top of the skin," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "NB-001 employs a physical mode of action to disrupt the outer membranes of pathogens and prompt viral lysis, essentially killing on contact."

The study also suggests that the physical mode of action of NB-001 significantly reduces the likelihood that pathogens will develop resistance to the biocidal effect of the topical lotion.

"These characteristics make NB-001 an ideal candidate for first-line treatment with the potential for
'/>"/>

SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy
2. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
3. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
6. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
7. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
8. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
9. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
10. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
11. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 The Pulmonary Fibrosis ... data from more than 1,100 patients and families suffering ... Drug Administration (FDA) for the Patient-Focused Drug Development Meeting ... a new FDA initiative to seek patient input in ... therapeutic treatments. "We applaud the FDA for ...
(Date:9/16/2014)... , Sept. 16, 2014 Astellas announced ... of Business Communications & Advocacy, Urology in the ... Communications & Advocacy Margaret Long. In this role, Noland ... urology to patient and advocacy organizations, as well ... key strategic initiatives. Noland,s appointment is the latest ...
(Date:9/16/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... an underwritten registered public offering of shares of ... being offered by Aratana Therapeutics. ... book-running managers for the offering.  ...
Breaking Medicine Technology:PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4Christy Noland to Lead Urology Advocacy and Communications for Astellas 2Aratana Therapeutics, Inc. Announces Proposed Public Offering 2
... Oct. 11 Merial, the Animal Health division ... ), announced today that Merial Animal Health Co. (China) held ... located in the Nanchang Hi-tech Development Zone, China. Merial ... the Group,s first production facility in China has been in ...
... , EXTON, Pa., Oct. 9 Kensey Nash Corporation (Nasdaq: ... earnings results for its first quarter ended September 30, 2009 ... , Joe Kaufmann, President and CEO, will be ... 22, 2009 at 9:00 A.M. Eastern Time. , ...
Cached Medicine Technology:Merial invests US $70 million in Nanchang, China 2Merial invests US $70 million in Nanchang, China 3Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference 2
(Date:9/16/2014)... 2014 The second federal bellwether trial ... Johnson subsidiary Ethicon concluded with the jury in the ... awarding her $3.27 million in damages, according to a ... “jurors found Ethicon liable for selling faulty devices and ... were at risk from side effects that include pain, ...
(Date:9/16/2014)... 16, 2014 Advanced Fertility Center of ... by Houstonia Magazine as one of the Top Doctors ... Magazine - a metropolitan magazine serving the Houston area. ... recognize them for their outstanding services. This accomplishment will ... of Houstonia Magazine — a special publication listing all ...
(Date:9/16/2014)... Duke’s Chowder House Lake Union is ... and Gratafy for a fun evening of tech networking. ... cemented. With the growth of companies in these sectors, there’s also ... work in tech and at startups to connect with each other. ... to host events for their peers to meet and mingle in ...
(Date:9/16/2014)... radiation therapy as part of breast conservation is ... hormone-receptor positive (HR+) invasive breast cancer. A new ... however, shows that combination may not be necessary ... , The results, which Fox Chase researchers presented ... Annual Meeting on Sunday, September 14, suggest that ...
(Date:9/16/2014)... This year’s theme is centered around entrepreneurism ... Mills, Pennsylvania, September 15, 2014- Holganix, an elite member ... growing companies in the country, produces an organic Bionutritional ... health-care by naturally decreasing disease and insect damage though ... that it will hold its third annual Bionutritional Summit ...
Breaking Medicine News(10 mins):Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 2Health News:Seattle Seafood Restaurant Duke’s Chowder House Partners with Rebls & Gratafy for Tech Networking Happy Hour Event. 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... Steven Reinberg HealthDay Reporter , MONDAY, March ... second of three reactors at earthquake-ravaged Japan,s Fukushima Dai-ichi ... the facility were safe, according to news reports. ... with seawater after Friday,s devastating earthquake and tsunami knocked ...
... major study of the wellbeing and inclusion of former ... by Queen,s University today (Monday 14 March). ... in Northern Ireland and the border region of Ireland ... of loyalist and republican former prisoners (aged 50 and ...
... Researchers at Georgia Health Sciences University are studying whether ... metabolite could halt the progression of diabetic nephropathy, or ... year, $308,000 grant from the American Heart Association, Dr. ... College of Dental Medicine and Pharmacology and Toxicology in ...
... International Liver CongressTM is an opportunity for over ... to hear the latest research, perspectives and treatments ... field. It features a high-calibre and multi-disciplinary scientific ... the most essential topics. EASL will hold ...
... taken by certain women as a preventive measure against breast ... conclusion of a new study published early online in ... The study,s results suggest that the benefits of tamoxifen to ... post-menopausal women under age 55 years who have an increased ...
... to resist the targeted drug Herceptin, but a single ... vulnerability to treatment, scientists at The University of Texas ... Nature Medicine . Adding the drug saracatinib to ... at least five different molecular pathways, each of which ...
Cached Medicine News:Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 2Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 3Health News:Explosion Rocks 2nd Nuclear Reactor in Japan 4Health News:Report into well-being and inclusion of former politically motivated prisoners 2Health News:Report into well-being and inclusion of former politically motivated prisoners 3Health News:International Liver Congress 2011 2Health News:Taking tamoxifen to prevent breast cancer can save lives and money 2Health News:Combination overcomes breast cancer resistance to herceptin 2Health News:Combination overcomes breast cancer resistance to herceptin 3
... Digisonics is a web-based application to securely ... cardiovascular modalities. Users can login from ... password to review stored patient studies. ... patient information, images, and reports Quickly locates ...
... stands for Stainless Steel Kleener. SSK-80 is ... and stain remover for ultra-sonic cleaners. , ... of your instruments by removing and inhibiting ... pivot points, box joints and moving instrument ...
... Foam is the ready-to-use, pre-cleaning enzymatic foam ... ,Hemaway Enzymatic Foam sprays on ... It's perfect for use in the O.R. ... Getting a head start with Hemaway Enzymatic ...
... Cytospin has been synonymous with ... More than 15,000 laboratories worldwide ... It provides economical thin-layer preparations ... hypocellular fluids such as spinal ...
Medicine Products: